title: The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.
abstract: OBJECTIVE
  Increases in neu/erbB-2 have been implicated in breast cancer prognosis, but do not predict all recurrences. On the basis of evidence that p53 mutation is involved in the development of human neoplasia, we examined the prognostic value of p53 alterations in combination with neu/erbB-2 amplification.
  
  
  METHODS
  A consecutive series of women were observed for recurrence and death (median follow-up of 85 months) and tumors from 543 individuals were analyzed for p53 mutation status and neu/erbB-2 amplification. Exons 4 through 10 of the p53 gene were analyzed by single-stranded conformational polymorphism and mutations were confirmed by DNA sequencing. The association of p53 mutation status and neu/erbB-2 amplification with risk of recurrence and death was examined in survival analyses with traditional and histologic markers as prognostic factors.
  
  
  RESULTS
  p53 mutations occurred in 24.5% of the axillary node-negative breast carcinomas. Mutations were more frequent in carcinomas with neu/erbB-2 amplification: 38.9% compared with only 20.9% in those without neu/erbB-2 amplification. We found elevated risks of disease recurrence and overall mortality in patients with both p53 mutation and neu/erbB-2 amplification in their tumor compared with patients with neither or only one of the alterations. This increase persisted with adjustment for other prognostic factors (relative risk, 2.32; P =.002 for recurrence; relative risk, 2.22; P =.004 for death).
  
  
  CONCLUSIONS
  Evaluation of tumors for p53 mutations may be beneficial to identify women at higher risk of disease recurrence and death when the tumor has neu/erbB-2 amplification, but in the absence of neu/erbB-2 amplification, the presence of p53 mutation may not provide additional independent prognostic information.
authors.affiliation: Fred A. Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada.
authors.forename: Shelley B
authors.initials: SB
authors.lastname: Bull
authors.forename: Hilmi
authors.initials: H
authors.lastname: Ozcelik
authors.forename: Dushanthi
authors.initials: D
authors.lastname: Pinnaduwage
authors.forename: Martin E
authors.initials: ME
authors.lastname: Blackstein
authors.forename: Donald A J
authors.initials: DA
authors.lastname: Sutherland
authors.forename: Kathleen I
authors.initials: KI
authors.lastname: Pritchard
authors.forename: Anjela T
authors.initials: AT
authors.lastname: Tzontcheva
authors.forename: Saul
authors.initials: S
authors.lastname: Sidlofsky
authors.forename: Wedad M
authors.initials: WM
authors.lastname: Hanna
authors.forename: Ali H
authors.initials: AH
authors.lastname: Qizilbash
authors.forename: Mary E
authors.initials: ME
authors.lastname: Tweeddale
authors.forename: Sheldon
authors.initials: S
authors.lastname: Fine
authors.forename: David R
authors.initials: DR
authors.lastname: McCready
authors.forename: Irene L
authors.initials: IL
authors.lastname: Andrulis
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000235:genetics*; D005260:Female; D005784:Gene Amplification; D018734:Genes, erbB-2 / Q000235:genetics*; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D004273:DNA, Neoplasm